Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. [Review]

MedStar author(s):
Citation: Journal of the American College of Cardiology. 75(9):1061-1073, 2020 03 10.PMID: 32138967Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Angioplasty, Balloon, Coronary | *Antineoplastic Agents/ad [Administration & Dosage] | *Coronary Artery Disease/th [Therapy] | *Paclitaxel/ad [Administration & Dosage] | *Sirolimus/ad [Administration & Dosage] | Drug-Eluting Stents | Humans | Randomized Controlled Trials as TopicYear: 2020Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:
  • 0735-1097
Name of journal: Journal of the American College of CardiologyAbstract: Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh. A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the wall after inflation and contact with the intima. DCB have demonstrated effectiveness in treating in-stent restenosis. Clinical studies using DCB in de novo coronary artery disease have shown mixed results, with a major benefit in small-vessel disease. Differences in study results are not only due to variations in DCB technology but also to disparity in procedural approach, "leave nothing behind" or "combination therapy," and vessel size. This review focuses on the available evidence from randomized trials and proposes a design for future clinical trials. Copyright (c) 2020. Published by Elsevier Inc.All authors: Case BC, Forrestal BJ, Garcia-Garcia HM, Torguson R, Waksman R, Weintraub WS, Yerasi COriginally published: Journal of the American College of Cardiology. 75(9):1061-1073, 2020 Mar 10.Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2020-07-09
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32138967 Available 32138967

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

Percutaneous coronary intervention with a drug-eluting stent is the most common mode of revascularization for coronary artery disease. However, restenosis rates remain high. Non-stent-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no metallic mesh. A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the wall after inflation and contact with the intima. DCB have demonstrated effectiveness in treating in-stent restenosis. Clinical studies using DCB in de novo coronary artery disease have shown mixed results, with a major benefit in small-vessel disease. Differences in study results are not only due to variations in DCB technology but also to disparity in procedural approach, "leave nothing behind" or "combination therapy," and vessel size. This review focuses on the available evidence from randomized trials and proposes a design for future clinical trials. Copyright (c) 2020. Published by Elsevier Inc.

English

Powered by Koha